Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Food Protection docket

This article was originally published in The Tan Sheet

Executive Summary

FDA established a public docket to receive information and comments related to its Food Protection Plan, according to an April 2 Federal Register notice. The plan published in November calls for providing the agency with mandatory recall power (1"The Tan Sheet" Nov. 12, 2007, p. 6). The agency asks for comments on three elements: prevention, intervention and response. Some of the questions include, "What, if any, significant gaps are there in the key prevention steps and the associated FDA actions listed in the plan?" and "What are potential data sources other than FDA data to inform the risk-based approach?" The deadline for comments is July 31...

You may also be interested in...



Mandatory Food Recall Power For FDA Better Than Using Existing Authorities?

FDA needs funding to execute the enforcement authorities it already has, not the additional authority it is asking for to order mandatory recalls of food products, including dietary supplements and vitamins, industry stakeholders say

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS101528

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel